SCHEMBL5947215

SCHEMBL5947215

Clc1ccc(CCNCc2cccc(Oc3ccccc3)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 9/20 0.62
▸ LTA4H P09960 2/20 0.58
▸ EPHX2 P34913 2/20 0.58
▸ KDM4E B2RXH2 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ HTT P42858 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ LMNA P02545 1/20 0.56
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ OPRM1 P35372 1/20 0.52
▸ OPRD1 P41143 1/20 0.52
▸ OPRK1 P41145 1/20 0.52
▸ PPARG P37231 1/20 0.50
▸ PPARA Q07869 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947260 0.91 BCHE (0.68) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947718 0.91 BCHE (0.72) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947283 0.89 BCHE (0.58) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947523 0.88 CYP1A2 (0.56) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947179 0.86 BCHE (0.56) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947593 0.86 LTA4H (0.79) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947564 0.86 BCHE (0.62) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947555 0.86 BCHE (0.78) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947437 0.86 BCHE (0.62) BCHELTA4HEPHX2KDM4EALDH1A1
SCHEMBL5947143 0.85 KDM4E (0.80) BCHELTA4HEPHX2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B BCHE 763/4885LTA4H 820/4885EPHX2 1402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback